Tag Archives: Axsome Therapeutics Inc.

Spotlight on three winning stocks from the past week and one absolute washout. But buy the dud first, then see what we think about the others.

1) Axsome Therapeutics Inc. (Nasdaq:AXSM) led advancing issues, skyrocketing 180% last week to $7.36. On Jan. 7, the NYC-based company reported that its lead drug candidate, AXS-05, hit its primary endpoint in… Read more »